 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
17 News |  |
- | Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Preclinical, Journal, Combination therapy: Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. (Pubmed Central) - Jan 11, 2024
Combined ALECSAT and anti-PDL1 therapy results in favorable anti-cancer responses in both cell line-derived xenograft and autologous PDX models of advanced triple-negative breast cancer.
- || Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Clinical, P2 data, Journal: A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. (Pubmed Central) - Nov 17, 2021
The treatment groups were balanced in terms of serious adverse events (52.4% vs 52.5%), but adverse events ≥grade 3 were more common in the experimental arm (81.0% vs 92.5%). Addition of ALECSAT immunotherapy to standard treatment with radiochemotherapy was well tolerated but did not improve PFS or OS for patients with newly diagnosed GBM.
- || Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
New P1/2 trial, Metastases: ImmunoBreast - A Phase Ib Study (clinicaltrials.gov) - Oct 29, 2020
P1/2, N=20, Recruiting, Sponsor: Henrik Ditzel
- ||| Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Trial completion, Trial completion date, Trial primary completion date: Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma (clinicaltrials.gov) - Apr 30, 2020
P2, N=62, Completed, Sponsor: CytoVac A/S
Addition of ALECSAT immunotherapy to standard treatment with radiochemotherapy was well tolerated but did not improve PFS or OS for patients with newly diagnosed GBM. Active, not recruiting --> Completed | Trial completion date: Jun 2021 --> Feb 2020 | Trial primary completion date: Jun 2020 --> Nov 2019
- || Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Trial completion: A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients (clinicaltrials.gov) - Feb 26, 2019
P1, N=10, Completed, Sponsor: CytoVac A/S
Active, not recruiting --> Completed | Trial completion date: Jun 2021 --> Feb 2020 | Trial primary completion date: Jun 2020 --> Nov 2019 Terminated --> Completed
- || Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Enrollment closed, Trial completion date, Trial primary completion date: Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma (clinicaltrials.gov) - Feb 26, 2019
P2, N=62, Active, not recruiting, Sponsor: CytoVac A/S
Terminated --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jan 2022 --> Jun 2021 | Trial primary completion date: Jan 2020 --> Jun 2020
- ||||| Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
New P2 trial: Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma (clinicaltrials.gov) - Jun 15, 2016
P2, N=87, Recruiting, Sponsor: CytoVac A/S
- Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac, Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Trial primary completion date, Tumor cell: Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan (clinicaltrials.gov) - Jun 17, 2015
P2, N=25, Terminated, Sponsor: CytoVac A/S
Recruiting --> Active, not recruiting | Trial completion date: Jan 2022 --> Jun 2021 | Trial primary completion date: Jan 2020 --> Jun 2020 N=175 --> 25 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jun 2015; Substantial design modifications required.
- Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Enrollment change, Trial termination: A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients (clinicaltrials.gov) - Apr 23, 2015
P1, N=10, Terminated, Sponsor: CytoVac A/S
N=175 --> 25 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jun 2015; Substantial design modifications required. N=18 --> 10 | Recruiting --> Terminated
- ||||| Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac, Avastin (bevacizumab) / Roche
New P2 trial, Tumor cell: Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan (clinicaltrials.gov) - Feb 10, 2014
P2, N=175, Recruiting, Sponsor: CytoVac A/S
- | Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
New P1 trial: A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients (clinicaltrials.gov) - Nov 13, 2013
P1, N=18, Recruiting, Sponsor: CytoVac A/S
- Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Enrollment change, Tumor cell: ALECSAT-GBM: A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients (clinicaltrials.gov) - Apr 3, 2013
P1, N=23, Completed, Sponsor: CytoVac A/S
N=18 --> 10 | Recruiting --> Terminated N=14 --> 23
- | Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Trial completion, Tumor cell: ALECSAT-GBM: A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients (clinicaltrials.gov) - Apr 3, 2013
P1, N=23, Completed, Sponsor: CytoVac A/S
N=14 --> 23 Enrolling by invitation --> Completed
- | Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Trial completion: Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (clinicaltrials.gov) - Apr 3, 2013
P1, N=21, Completed, Sponsor: CytoVac A/S
Enrolling by invitation --> Completed Enrolling by invitation --> Completed
- | Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
New P1 trial, Tumor cell: ALECSAT-GBM: A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients (clinicaltrials.gov) - Apr 29, 2012
P1, N=23, Completed, Sponsor: CytoVac A/S
- | Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
Trial completion: ALECSAT: Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (clinicaltrials.gov) - Apr 25, 2012
P1, N=13, Completed, Sponsor: CytoVac A/S
Enrolling by invitation --> Completed Enrolling by invitation --> Completed
- | Alecsat (cytotoxic lymphocyte-based cancer vaccine) / CytoVac
New P1 trial: Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy (clinicaltrials.gov) - Aug 22, 2011
P1, N=21, Completed, Sponsor: CytoVac A/S